Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More